Brand Name | Status | Last Update |
---|---|---|
bortezomib | ANDA | 2025-03-27 |
boruzu | New Drug Application | 2024-09-27 |
velcade | New Drug Application | 2022-10-25 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
multiple myeloma | — | D009101 | C90.0 |
mantle-cell lymphoma | — | D020522 | C83.1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 4 | 3 | — | 2 | 2 | 10 |
Plasma cell neoplasms | D054219 | — | — | 4 | 3 | — | 2 | 1 | 9 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
Drug common name | Bortezomib |
INN | bortezomib |
Description | Bortezomib is l-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome. It has a role as an antineoplastic agent, a proteasome inhibitor, a protease inhibitor and an antiprotozoal drug. It is an amino acid amide, a member of pyrazines and a L-phenylalanine derivative. It is functionally related to a boronic acid. |
Classification | Small molecule |
Drug class | proteozome inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O |
PDB | — |
CAS-ID | 179324-69-7 |
RxCUI | — |
ChEMBL ID | CHEMBL325041 |
ChEBI ID | 52717 |
PubChem CID | 387447 |
DrugBank | DB00188 |
UNII ID | 69G8BD63PP (ChemIDplus, GSRS) |